| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA898: Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | dabrafenib (Tafinlar®) |
| Formulation | Capsule |
| Reference number | 2509 |
| Indication | In combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | Non-submission |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/05/2023 |
| NICE guidance | |